Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- PMID: 24332512
- PMCID: PMC3922714
- DOI: 10.1016/S1470-2045(13)70551-5
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Abstract
Background: Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour microenvironment. These checkpoints might include effects of programmed cell death 1 (PD1), a co-inhibitory receptor that impairs T-cell function and is highly expressed on intratumoral T cells. We did this phase 2 trial to investigate the activity of pidilizumab, a humanised anti-PD1 monoclonal antibody, with rituximab in patients with relapsed follicular lymphoma.
Methods: We did this open-label, non-randomised trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Adult (≥18 years) patients with rituximab-sensitive follicular lymphoma relapsing after one to four previous therapies were eligible. Pidilizumab was administered at 3 mg/kg intravenously every 4 weeks for four infusions, plus eight optional infusions every 4 weeks for patients with stable disease or better. Starting 17 days after the first infusion of pidilizumab, rituximab was given at 375 mg/m(2) intravenously weekly for 4 weeks. The primary endpoint was the proportion of patients who achieved an objective response (complete response plus partial response according to Revised Response Criteria for Malignant Lymphoma). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00904722.
Findings: We enrolled 32 patients between Jan 13, 2010, and Jan 20, 2012. Median follow-up was 15.4 months (IQR 10.1-21.0). The combination of pidilizumab and rituximab was well tolerated, with no autoimmune or treatment-related adverse events of grade 3 or 4. The most common adverse events of grade 1 were anaemia (14 patients) and fatigue (13 patients), and the most common adverse event of grade 2 was respiratory infection (five patients). Of the 29 patients evaluable for activity, 19 (66%) achieved an objective response: complete responses were noted in 15 (52%) patients and partial responses in four (14%).
Interpretation: The combination of pidilizumab plus rituximab is well tolerated and active in patients with relapsed follicular lymphoma. Our results suggest that immune checkpoint blockade is worthy of further study in follicular lymphoma.
Funding: National Institutes of Health, Leukemia and Lymphoma Society, Cure Tech, and University of Texas MD Anderson Cancer Center.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Conflict of interest statement
SSN received research support from Cure Tech Ltd, Yavne, Israel. RRY is an employee of Cure Tech Ltd.
Figures
Comment in
-
Anti-PD1 antibody: a new approach to treatment of lymphomas.Lancet Oncol. 2014 Jan;15(1):7-8. doi: 10.1016/S1470-2045(13)70587-4. Epub 2013 Dec 11. Lancet Oncol. 2014. PMID: 24332517 No abstract available.
-
Haematological malignancies: Double act in follicular lymphoma.Nat Rev Clin Oncol. 2014 Feb;11(2):64. doi: 10.1038/nrclinonc.2014.1. Epub 2014 Jan 21. Nat Rev Clin Oncol. 2014. PMID: 24445521 No abstract available.
Similar articles
-
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1. Lancet Oncol. 2011. PMID: 21724462 Clinical Trial.
-
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439689 Free PMC article. Clinical Trial.
-
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5. Lancet Haematol. 2018. PMID: 30172345 Clinical Trial.
-
Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000. Drugs. 2010. PMID: 20614951 Review.
-
Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.J Natl Cancer Inst. 2009 Feb 18;101(4):248-55. doi: 10.1093/jnci/djn478. Epub 2009 Feb 10. J Natl Cancer Inst. 2009. PMID: 19211444 Review.
Cited by
-
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.Signal Transduct Target Ther. 2024 Sep 4;9(1):229. doi: 10.1038/s41392-024-01941-x. Signal Transduct Target Ther. 2024. PMID: 39227388 Free PMC article. Clinical Trial.
-
Prediction of PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma by diffusion and perfusion MRI: a preliminary study.BMC Med Imaging. 2024 Aug 26;24(1):222. doi: 10.1186/s12880-024-01409-y. BMC Med Imaging. 2024. PMID: 39187807 Free PMC article.
-
Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas.Front Oncol. 2024 Jul 18;14:1420920. doi: 10.3389/fonc.2024.1420920. eCollection 2024. Front Oncol. 2024. PMID: 39091917 Free PMC article. Review.
-
Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study.Cancers (Basel). 2024 May 16;16(10):1892. doi: 10.3390/cancers16101892. Cancers (Basel). 2024. PMID: 38791970 Free PMC article.
-
Autophagy as a Target for Non-Immune Intrinsic Functions of Programmed Cell Death-Ligand 1 in Cancer.Int J Mol Sci. 2023 Oct 9;24(19):15016. doi: 10.3390/ijms241915016. Int J Mol Sci. 2023. PMID: 37834467 Free PMC article. Review.
References
-
- Horning SJ, Rosenberg SA. The Natural History of Initially Untreated Low-Grade Non-Hodgkin’s Lymphomas. New England Journal of Medicine. 1984;311(23):1471–5. - PubMed
-
- Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60. - PubMed
-
- Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159–69. - PubMed
-
- Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007;13(2 Pt 1):388–97. - PubMed
-
- Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24(34):5350–7. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources